Covid-19 plasma therapy has shown little benefit in patients
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Convalescent plasma therapy as a potential treatment has shown a limited effect in reducing the progression to severe disease or death in a trial conducted in India, according to a study, published in the British Medical Journal (BMJ)

Study involved 464 adults with moderate Covid-19 who were admitted to hospitals in India between April and July. As many as 239 adult patients received two transfusions of convalescent plasma, 24 hours apart, alongside standard care, while the control group comprising of 229 patients received standard care only.

One month later, 19% of those who received the plasma had progressed to severe disease or had died of any cause, compared with 18% in the control group.

Plasma therapy did, however, seem to reduce symptoms, such as shortness of breath and fatigue, after seven days, according to the researchers, including those from ICMR, and National Institute of Epidemiology, Tamil Nadu.

"Convalescent plasma was not associated with a reduction in progression to severe Covid-19 or all-cause mortality," the researchers wrote in the journal.

The researchers noted that a prior measurement of neutralising antibody titres in donors and participants might further clarify the role of convalescent plasma in the management of Covid-19.

Although the observational studies conducted previously suggested clinical benefits in recipients of convalescent plasma, the trials were stopped early and failed to ascertain any mortality benefit from plasma treatment in patients with Covid-19, the researchers said.

The new study shows that in settings with limited laboratory capacity, convalescent plasma does not reduce 28-day mortality or progression to severe disease in patients admitted to hospital with moderate Covid-19, they said.

1 share